Eli Lilly and Company (FRA:LLY)
Germany · Delayed Price · Currency is EUR | Market Cap | 544.79B |
| Revenue (ttm) | 45.35B |
| Net Income (ttm) | 11.75B |
| Shares Out | n/a |
| EPS (ttm) | 13.02 |
| PE Ratio | 46.36 |
| Forward PE | 27.95 |
| Dividend | 5.29 (0.87%) |
| Ex-Dividend Date | Aug 15, 2025 |
| Volume | 493 |
| Average Volume | 732 |
| Open | 611.10 |
| Previous Close | 614.30 |
| Day's Range | 608.00 - 614.40 |
| 52-Week Range | 537.40 - 888.80 |
| Beta | n/a |
| RSI | 46.64 |
| Earnings Date | Aug 7, 2025 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]
Financial Performance
In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.
Financial numbers in USD Financial StatementsNews
The Big 3: LLY, BA, CVS
Dan Deming considers Friday's trading action after Jerome Powell's Jackson Hole speech "remarkable." On stocks he's watching ahead, he expects Eli Lilly (LLY) to rebound off a significant sell-off, Bo...
Lilly to participate in Wells Fargo 20th Annual Healthcare Conference
INDIANAPOLIS , Aug. 22, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Wells Fargo 20th Annual Healthcare Conference on Sept. 5, 2025. Patrik Jonsson, executive vice pre...
J&J Commits $2 Billion To US Manufacturing Expansion Amid Threat Of Drug Tariffs
Johnson & Johnson (NYSE: JNJ) is set to invest $2 billion in its North Carolina facilities, expanding its U.S. manufacturing operations. This move comes in response to potential drug import tariffs p...
Eli Lilly and Company Investors: Company Investigated by the Portnoy Law Firm
Investors can contact the law firm at no cost to learn more about recovering their losses
Behind The Pick: Eli Lilly - Confidence In The Dip
Healthcare Stocks Are Trading at Their Biggest Discount in 30 Years. Why a Turnaround May Have Already Started.
For investors worried about elevated market valuations, they may be just what the doctor ordered.
Eli Lilly begins executive search as neuro chief Anne White retires
One of the Best Stocks to Buy Now?
I ranked Eli Lilly as one of the best stocks to buy starting in 2025.
What's Going on With Eli Lilly Stock?
The pharma company is gaining investor attention due to increasingly popular products.
Anne White to Retire as Executive Vice President and President, Lilly Neuroscience
INDIANAPOLIS , Aug. 20, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that Anne White, executive vice president and president, Lilly Neuroscience, will be retiring from Lilly ...
Eli Lilly Ranks Among Top Large-Cap Performers as GLP-1 Drug Sales Exceed Billions
Eli Lilly (NYSE:LLY) has quickly emerged as one of Wall Street’s biggest winners, fueled by explosive demand for its new generation of weight-loss and diabetes treatments. The company’s GLP-1 drugs, i...
Pharmaceuticals Industry Analysis: Eli Lilly Tops My Tier Two
Viking's 42% Plunge Splits Experts—A '$129 Strong Buy' Or 'Clearly Inferior' Drug?
Viking Therapeutics Inc. (NASDAQ: VKTX) saw its stock collapse by over 42% on Tuesday after data from its Phase 2 obesity pill trial disappointed investors, sparking a fierce debate between Wall Stre...
New Obesity Drugs May See Premium Pricing Undermined By Underwhelming Data
Eli Lilly and Novo Nordisk are expected to price their ... Full story available on Benzinga.com
New Obesity Drugs May See Premium Pricing Undermined By Underwhelming Data
Eli Lilly and Co. LLY and Novo Nordisk A/S NVO are expected to launch new obesity-treatment pills in the U.S. next year at prices comparable to their existing injectable drugs, signaling a break from ...
How does Viking’s oral obesity drug stand up to those of Eli Lilly and Novo?
Ozempic Gains First Approval In Canada For Kidney Disease And Cardiovascular Death Risk
Health Canada on Tuesday approved Novo Nordisk 's (NYSE: NVO) Ozempic (semaglutide) to reduce the risk of kidney disease and cardiovascular deaths in adults with type 2 diabetes . The approval makes ...
Eli Lilly Stock Investors Need to See This
Competition among the makers of weight loss treatments is intensifying.
Viking Therapeutics shares fall more than 30% on disappointing obesity pill trial data
The results could reinforce Eli Lilly and Novo Nordisk's dominance in the booming market for weight loss and diabetes drugs.
Like Eli Lilly, Viking Therapeutics' Oral Weight Loss Drug Disappoints, Stock Tanks
On Tuesday, Viking Therapeutics Inc. (NASDAQ: VKTX) released the much-awaited data from its Phase 2 trial of VK2735 pill, the company’s dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose...
Like Eli Lilly, Viking Therapeutics' Oral Weight Loss Drug Disappoints, Stock Tanks
On Tuesday, Viking Therapeutics Inc. VKTX released the much-awaited data from its Phase 2 trial of VK2735 pill, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent ...
Weight loss drugs: how will you be affected by the Mounjaro price rise in the UK?
We’d like to hear from people who are taking Mounjaro and how they feel about the increase in cost for doses Eli Lilly, the US manufacturer of the weight loss jab Mounjaro, has said the price will ris...
Eli Lilly Considering Viking Therapeutics Acquisition? Expert Says 'They're Setting Up For Something BIG' As LLY Issues 40-Year Bond
Eli Lilly And Co. ‘s (NYSE: LLY) recent, and highly unusual, issuance of a 40-year bond is fueling speculation that the pharmaceutical giant may be preparing for a major acquisition, with Viking Ther...